Key Summary:
- Valepotriate showed activity against drug-resistant TB.
- High concentrations eliminated viable bacteria within 24 hours.
- The compound could support future TB drug development.

A naturally occurring compound has demonstrated promising activity against drug-resistant tuberculosis (TB), offering a potential new avenue for antimicrobial development as resistance continues to threaten the effectiveness of existing treatments.
The study, published in JAC-Antimicrobial Resistance, identified valepotriate as a novel antimycobacterial lead compound capable of rapidly killing Mycobacterium tuberculosis (M. tuberculosis), including clinical isolates resistant to existing antibiotics.
The findings, published ahead of World Antimicrobial Resistance Awareness Week 2026, highlight the potential of natural products as starting points for developing new treatments against one of the world’s most challenging drug-resistant infections.
Researchers screened a library of 354 naturally occurring terpenoid compounds to identify candidates with activity against M. tuberculosis. Terpenoids represent one of the largest classes of natural products and exhibit a wide range of biological activities, although their potential against TB has not been systematically explored.
Initial screening identified 10 compounds with strong antimycobacterial activity, with valepotriate emerging as a particularly promising candidate.
Further laboratory testing demonstrated that valepotriate inhibited the growth of extracellular M. tuberculosis at a minimum inhibitory concentration (MIC) of 10 μM, while its minimum bactericidal concentration (MBC) was 20 μM.
These results indicated that the compound could both inhibit bacterial growth and kill the pathogen, supporting further investigation into its therapeutic potential.
Time–kill experiments demonstrated rapid, concentration-dependent bactericidal activity.
At four times the MIC, valepotriate reduced viable bacterial counts by more than 2 log10 colony-forming units within 24 hours, representing a reduction of more than 99%. At concentrations eight and 16 times the MIC, no viable bacteria were detected after 24 hours under the experimental conditions.
Importantly, the compound retained activity against 14 clinical isolates of M. tuberculosis, including both drug-susceptible and drug-resistant strains. MIC values ranged from 5–20 μM, suggesting that valepotriate may act against strains with resistance to existing treatments.
The researchers also investigated its ability to target intracellular bacteria, an important consideration because M. tuberculosis can survive within host immune cells.
Using macrophages derived from THP-1 cells, the team demonstrated that valepotriate significantly reduced the intracellular bacterial burden at bactericidal concentrations that were well tolerated by the cells.
These findings suggest that the compound could potentially target bacteria within host cells, although further studies are needed to establish its safety and effectiveness in living organisms.
The emergence and spread of multidrug-resistant TB remain major challenges for global infection control, particularly as resistance reduces the effectiveness of established antibiotic regimens.
Identifying compounds with activity against resistant M. tuberculosis is therefore an important research priority.
The findings position valepotriate as a potential starting point for the development of new antimycobacterial agents. However, the researchers emphasised the need for further optimisation of its antibacterial potency before its therapeutic potential can be fully assessed.
Additional research will also be required to determine its mechanism of action, pharmacological properties, safety, and efficacy in animal models before clinical development can be considered.
As World Antimicrobial Resistance Awareness Week draws attention to the urgent need for new antimicrobial strategies, the study highlights the value of exploring natural compound libraries to identify previously underinvestigated antibacterial candidates.
Although valepotriate remains at an early, preclinical stage of development, its rapid bactericidal activity and effectiveness against drug-resistant clinical isolates provide a promising foundation for further TB drug discovery.
Reference
Zhu C, Wang X, Zhang X, et al. Identification of valepotriate as a novel antimycobacterial agent against drug-resistant Mycobacterium tuberculosis through screening of a natural terpenoid compound library. JAC Antimicrob Resist. 2026;8(6):dlag250. doi: 10.1093/jacamr/dlag250.
Adobe Stock
Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.